Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio (Nasdaq: ASRT) said Garda Therapeutics intends to commence a tender offer to acquire all outstanding shares on April 29, 2026, after a 20-day window-shop period. The agreed purchase price is $18.00 per share, totaling $125.1 million in cash, plus a contingent value right. The window-shop permits Assertio to solicit superior bids; if the Board accepts a superior proposal and terminates the Garda Agreement, a reduced breakup fee would apply.
Cosette Pharmaceuticals closed an agreement to acquire U.S. sales and distribution rights for seven branded products from Assertio (Nasdaq: ASRT), adding a portfolio with $48.9 million in 2025 net sales. The deal includes SYMPAZAN® oral film, which establishes a Neurology rare disease footprint and carries patent protection through 2040.
The portfolio also includes INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® (OTREXUP was discontinued in Aug 2025). A transition period will move manufacturing, supply, quality, pharmacovigilance, and regulatory responsibilities to Cosette.
Assertio (Nasdaq: ASRT) agreed to be acquired by Garda Therapeutics for $18 per share in cash (total $125.1 million) plus a contingent value right (CVR) tied to Sprix milestones. The offer represents a 34.6% premium to the unaffected price and includes a 20-day window-shop period. Assertio also sold non-Rolvedon assets to Cosette for $35 million upfront plus earnouts. Closing is expected in Q2 2026, subject to a majority tender and customary conditions; Assertio stock will be delisted after closing.
Assertio (Nasdaq: ASRT) reported Q4 and full-year 2025 results and issued 2026 guidance. Full-year 2025 net product sales were $117.1M and Adjusted EBITDA was $22.7M. Rolvedon sales totaled $68.2M in 2025. Cash and short-term investments were $63.4M at year-end. For 2026 the company expects Net Product Sales $110M–$125M and Adjusted EBITDA $28M–$40M.
Q4 trends included a Rolvedon quarter‑end sell‑in that reduced Q4 Rolvedon sales and working capital variability into early 2026.
Assertio Holdings (Nasdaq: ASRT) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close.
Management will host a live webcast and earnings call at 4:30 p.m. Eastern Time; telephone dial-in and a webcast replay (available ~two hours after the call) are provided on the company investor website.
Assertio Holdings (NASDAQ: ASRT) announced that as of January 12, 2026 Nasdaq has determined the company has regained compliance with all applicable listing requirements.
Nasdaq confirmed Assertio met the Minimum Bid Price Rule requiring a minimum bid of $1.00 per share for at least ten consecutive days, and that the matter is now closed. Management said compliance was achieved following the December 2025 reverse stock-split, while preserving capital allocation flexibility.
Assertio (Nasdaq: ASRT) announced publication in The Oncologist of a phase 1, multicenter (13 U.S. sites) trial (NCT04187898) testing same-day dosing of Rolvedon (eflapegrastim-xnst) given 30 minutes after TC chemotherapy in early-stage breast cancer. In 53 enrolled patients (49 completed), the mean time to ANC recovery in Cycle 1 was 1.8 days. Febrile neutropenia occurred in 1 patient; no neutropenic complications, hospitalizations, or antibiotic therapy were reported. The publication follows a December 2024 SABCS presentation. The company noted no new safety signals; randomized trials were not conducted.
Assertio (NASDAQ: ASRT) filed a certificate amendment on December 19 to implement a 1-for-15 reverse stock split of its common stock, effective 12:01 a.m. ET on December 26, 2025. Trading will be on a split-adjusted basis when markets open December 26, 2025, and the ticker ASRT will remain unchanged. The new CUSIP will be 04546C 304. The company said the reverse split aims to maintain its Nasdaq listing and support commercial progress around Rolvedon. Proportionate adjustments will be made to the conversion rate of the company’s 6.5% Convertible Senior Notes due 2027 and to shares authorized/reserved under equity plans and outstanding awards. No fractional shares will be issued; fractional entitlements will be paid in cash based on the December 24, 2025 Nasdaq closing price. Continental Stock Transfer & Trust will act as exchange agent.
Assertio (Nasdaq: ASRT) reported third quarter 2025 results and provided updated full‑year guidance on November 10, 2025. Key highlights include Rolvedon net product sales of $38.6M in Q3 (up from $15.0M a year earlier) and Adjusted EBITDA of $20.9M for the quarter. The company narrowed FY2025 guidance to Net Product Sales $110.0M–$112.0M and Adjusted EBITDA $14.0M–$16.0M. Cash and short‑term investments were $93.4M at September 30, 2025. Management advanced integration to consolidate subsidiaries and promoted Paul Schwichtenberg to President & COO.
Assertio (Nasdaq: ASRT) appointed director Mark L. Reisenauer as CEO effective immediately; current CEO Brendan P. O’Grady will depart.
The company said it will release third-quarter 2025 results on November 10, 2025 after market close and host a live webcast at 4:30 p.m. ET the same day. Management expects to update guidance within the current range on that call. Reisenauer joined the Board in January 2025 and has over 30 years of commercial experience, including growing U.S. commercial sales to nearly $5 billion at Astellas.